Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea · Delayed Price · Currency is KRW 1,773.00
-24.00 (-1.34%)
Apr 29, 2026, 3:30 PM KST
Xcell Therapeutics Revenue
In the year 2025, Xcell Therapeutics had annual revenue of 1.95B KRW with 0.76% growth. Xcell Therapeutics had revenue of 1.06B in the quarter ending December 31, 2025, with 123.15% growth.
Revenue
1.95B
Revenue Growth
+0.76%
P/S Ratio
15.73
Revenue / Employee
n/a
Employees
n/a
Market Cap
30.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.95B | 14.65M | 0.76% |
| Dec 31, 2024 | 1.93B | 810.45M | 72.11% |
| Dec 31, 2023 | 1.12B | 103.86M | 10.18% |
| Dec 31, 2022 | 1.02B | -946.25M | -48.12% |
| Dec 31, 2021 | 1.97B | 1.43B | 264.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 195.27B |
| ORIENT BIO | 59.09B |
| Amicogen | 41.98B |
| CG Invites | 27.39B |
| GeneOne Life Science | 23.04B |
| iNtRON Biotechnology | 5.74B |
| IMB Dx | 5.33B |
| ENCell | 5.26B |